

## Research Article

# Molecular Assessment of Domain I of Apical Membrane Antigen I Gene in *Plasmodium falciparum*: Implications in *Plasmodium* Invasion, Taxonomy, Vaccine Development, and Drug Discovery

Che Roland Achungu <sup>1,2,3</sup> Damian Nota Anong,<sup>1,4</sup> Robert Adamu Shey,<sup>5</sup> and Cevie Jesenta Tabe<sup>1,2</sup>

<sup>1</sup>Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon

<sup>2</sup>Laboratory of Molecular Parasitology, University of Buea, Buea, Cameroon

<sup>3</sup>Florence Nightingale Higher Institute of Health and Biomedical Sciences, Bamenda, Cameroon

<sup>4</sup>Department of Biological Sciences, The University of Bamenda, Bamenda, Cameroon

<sup>5</sup>Department of Biochemistry and Molecular Biology, Faculty of Science, University of Buea, Buea, Cameroon

Correspondence should be addressed to Che Roland Achungu; [cherolandachungu@gmail.com](mailto:cherolandachungu@gmail.com)

Received 15 April 2022; Revised 28 August 2022; Accepted 2 September 2022; Published 7 October 2022

Academic Editor: Lalit Batra

Copyright © 2022 Che Roland Achungu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Given its global morbidity and mortality rates, malaria continues to be a major public health concern. Despite significant progress in the fight against malaria, efforts to control and eradicate the disease globally are in jeopardy due to lack of a universal vaccine. The conserved short peptide sequences found in Domain I of *Plasmodium falciparum* apical membrane antigen 1 (PfAMA1), which are exposed on the parasite cell surface and in charge of *Plasmodium falciparum* invasion of host cells, make PfAMA1 a promising vaccine candidate antigen. The precise amino acids that make up these conserved short peptides are still unknown, and it is still difficult to pinpoint the molecular processes by which PfAMA1 interacts with the human host cell during invasion. The creation of a universal malaria vaccine based on the AMA1 antigen is challenging due to these knowledge limitations. This study used genome mining techniques to look for these particular short peptides in PfAMA1. Thirty individuals with *Plasmodium falciparum* malaria had blood samples taken using Whatman's filter papers. DNA from the parasite was taken out using the Chelex technique. Domain I of the *Plasmodium falciparum* AMA1 gene was amplified using nested polymerase chain reactions, and the amplified products were removed, purified, and sequenced. The DNA sequence generated was converted into the matching amino acid sequence using bioinformatic techniques. These amino acid sequences were utilized to search for antigenic epitopes, therapeutic targets, and conserved short peptides in Domain I of PfAMA1. The results of this investigation shed important light on the molecular mechanisms behind *Plasmodium* invasion of host cells, a potential PfAMA1 vaccine antigen sequence, and prospective malaria treatment options in the future. Our work offers fresh information on malaria medication and vaccine research that has not been previously discussed.

## 1. Introduction

Given its high global morbidity and mortality rates, malaria continues to be a major public health concern. Malaria is a parasite disease spread by mosquitoes. *Plasmodium falciparum*, *Plasmodium vivax*, *Plasmodium malariae*, *Plasmodium ovale*, and *Plasmodium knowlesi* are the five protozoa that cause malaria in humans [1]. *Plasmodium vivax* is the

leading cause worldwide, whereas *Plasmodium falciparum*, which causes more than 90% of global malaria death, continues to be the single most significant hazard to public health on a global level [1]. Malaria often causes severe disease, including high fever, shivering chills, and flu-like symptoms. The predicted number of malaria cases and deaths globally in 2020 was 241 million and 627,000, respectively [2]. With the development of antimalarial

medications like artemisinin, the implementation of efficient vector control strategies, and, most recently, the WHO's approval of RTS,S/AS01 vaccine to be used as the first malaria vaccine for children under five years of age [2], with 39% efficacy against malaria [3], control efforts have produced significant gains in the fight against malaria globally. However, the development and potential spread of artemisinin resistance in the malaria parasite, pesticide resistance in the mosquito vector, and the insufficient protection provided by the RTS,S/AS01 vaccine put these accomplishments in jeopardy. These characteristics obstruct attempts to control and eradicate malaria globally, underscoring the critical need for the creation of malaria vaccines that are both highly effective and secure.

The majority of the malaria vaccines that have undergone field trials have demonstrated modest efficacy. Polymorphisms in the genes that code for the vaccine candidate antigens could be one cause of the low efficacy. Apical membrane antigen 1 (AMA1) is a significant vaccine candidate antigen. AMA1 is an integral membrane protein with a 55-amino acid cytoplasmic segment and a 550-amino acid extracellular region that can be divided into three domains (Domains I, II, and III) based on intradomain disulphite bonds [4]. AMA1 is expressed in the late schizont stage of the parasite and necessary for merozoites to invade erythrocytes and sporozoites to invade hepatocytes [5], despite the fact that its role is still poorly understood. It has been demonstrated that antibodies against AMA1 prevent parasite invasion of human erythrocytes [6]. Because AMA1 is involved in both the invasion of hepatocytes by sporozoites and the invasion of erythrocytes by merozoites, it offers a special possibility as a candidate antigen for a multistage vaccine. The polymorphisms found in the AMA1 gene [7] and the lack of precise knowledge of the molecular mechanisms governing AMA1 interaction with host cells have made it challenging to develop an effective malaria vaccine over time. The majority of the single-nucleotide polymorphisms (SNPs) have been shown to be present in the highly immunogenic Domain I of AMA1 [8]. Additionally, RON2 has a binding site in Domain I of AMA1, which is necessary for the creation of actin-myosin-associated moving junctions, which are crucial for parasite invasion of host cells. A conserved area of Domain I of AMA1 that is surrounded by highly polymorphic regions is where RON2 binds [9]. It is yet unknown which short peptide sequences make up this conserved region of Domain I of AMA1 that interacts with RON2. Furthermore, it is still unclear how AMA1 interacts with host cells during parasite invasion through molecular pathways. These knowledge gaps hamper the creation of medicines and vaccines that target AMA1. This study sought to determine whether the conserved short peptide sequences in Domain I of PfAMA1 that bind to RON2 could be helpful for the production of vaccines and the discovery of new medicines.

## 2. Methods

**2.1. Study Area.** The research was done at Bamenda. The capital of Cameroon's Northwest Region, Bamenda, is located between latitude 6 N and longitude 10.1 E. 1472 meters

above the sea level is the average altitude. The climate is classified as a tropical monsoon with two seasons: dry season from November to March and rainy season from April to October. The annual rainfall is 2300 mm. Bamenda, which has a population of about 900000, is 366 kilometers northwest of Yaounde, the capital of Cameroon. Because it is an urban region with individuals from several ethnic groups, its population is genetically varied. The spread of malaria is ongoing. The frequency of malaria rises in the wet season and declines in the dry season. From June through August 2019, blood samples were taken from participants in the study.

**2.2. Sample Collection and Processing.** Venous blood samples were taken from 15 boys and 15 girls aged 0 to 5 years who are all from the semi-Bantu ethnic group with no history of immune suppression diseases and displayed malarial symptoms and clinical indications. A total of 30 blood samples were collected. The blood samples were subjected to rapid diagnostic tests and microscopic examination through thick and thin blood films. Blood samples positive for *Plasmodium falciparum* were spotted on Whatman filter papers packaged individually in a zip-locked bags and appropriately labeled. The samples were examined at the University of Buea's Molecular Parasitology Laboratory.

**2.3. Malaria Parasite DNA Extraction.** *Plasmodium falciparum* genomic DNA was extracted using the Chelex method of DNA extraction as described previously [10]. Agarose gel electrophoresis was used to confirm the existence of genomic DNA. The extracted DNA was kept at  $-20^{\circ}\text{C}$  until it was needed.

**2.4. Genotyping.** This was done using the nested PCR approach as described previously [7].

**2.5. Primary PCR.** The PCRs were carried out on a Gene AMP® PCR 9700 Applied Biosystem Machine. The PCR mixture contained  $10\ \mu\text{l}$  of OneTaq Hot Start Quick-Load (from New England Biolabs),  $0.8\ \mu\text{l}$  of forward primers,  $0.8\ \mu\text{l}$  of reverse primers,  $1\ \mu\text{l}$  of DNA template from the extracted DNA, and  $7.4\ \mu\text{l}$  of nuclease-free water making a total volume of  $20\ \mu\text{l}$ . The primers used amplified the complete PfAMA1 gene. The PCR was programmed for 25 cycles.

**2.6. Secondary PCR.** The PCRs were carried out on a Gene AMP® PCR 9700 Applied Biosystem Machine. The PCR mixture contained  $10\ \mu\text{l}$  of OneTaq Hot Start Quick-Load (from New England Biolabs),  $0.8\ \mu\text{l}$  of forward primers,  $0.8\ \mu\text{l}$  of reverse primers,  $1\ \mu\text{l}$  of DNA template obtained from the product of the first round of PCR, and  $7.4\ \mu\text{l}$  of nuclease-free water making a total volume of  $20\ \mu\text{l}$ . The primers used amplified Domain I of PfAMA1 where majority of genetic diversity occurred. The PCR was programmed for 30 cycles. Cycling conditions for both PCRs

TABLE 1: Primers used to genotype the *Plasmodium falciparum* AMA1 gene.

| Target              | Primers | Sequence 5'-3'               |
|---------------------|---------|------------------------------|
| Whole PfAMA1 gene   | Forward | CCGGATCCCCTTTGAGTTTACATATATG |
| First round of PCR  | Reverse | AAATTCTTTCTAGGGCAAAC         |
| Domain I of PfAMA1  | Forward | GGAACTCAATATAGACTTCC         |
| Second round of PCR | Reverse | AAATTCTTTCTAGGGCAAAC         |




FIGURE 1: Exemplary gel showing AMA1 fragments produced after the second round of PCR (created by the authors of this work). L<sub>1</sub>: molecular weight marker (10,000 bp); L<sub>3</sub>: variants with 700 bp and 400 bp; L<sub>4</sub>: variant with 400 bp; L<sub>5</sub>: variant with 700 bp; L<sub>7</sub>: variant with 400 bp; L<sub>12</sub>: negative control.

were as follows: initial denaturation at 95°C for 5 minutes, followed by 25 cycles (first round) or 30 cycles (second round) of denaturation at 94°C for 1 minute, annealing at 58°C for 2 minutes, and extension at 72°C for 2 minutes. The final extension was carried out at 72°C for 5 minutes and held at 5°C. The negative control's PCR settings were the same as those used in the experiment, but it did not contain any of the genomic DNA that was extracted from *Plasmodium falciparum*. The primers used are shown in Table 1.

**2.7. Visualizing AMA1 PCR Products Using Agarose Electrophoresis.** The amplified products of the secondary PCR were visualized using 1.5% agarose gel by electrophoresis. The agarose gel contained 1.5% agarose mixed with 1 μ of ethidium bromide. Electrophoresis ran for 40 minutes at 100 V. The migration occurred in a gel filled with 1X TBA buffer. A molecular weight marker (10000 bp) was loaded in the first well. The migrated DNA products were visualized using the gel documentation system (Bio-Rad, USA). The migrated amplified DNA fragments are shown in Figure 1.

Two major bands were identified: one approximately of 700 bp and the other approximately of 450 bp. The two bands were cut and removed from lane 3 (L<sub>3</sub>) of the gel. The bands were purified and sequenced on a BigDye V3.1 sequence machine using the forward primer GGAACTCAATATAGACTTCC and analysed on an ABI 3130XL Genetic Analyzer.

**2.8. Analysis.** The *Plasmodium falciparum* apical membrane antigen 1 (AMA1) nucleotide sequence data were arranged

using the BioEdit software tool. NCBI-BLAST (National Center for Biotechnology Information-Basic Local Alignment Search Tool) was used to find regions of local similarity to the *Plasmodium falciparum* 3D7 reference genome and other related sequences in the NCBI database. The protein coding sequence (CDS) was identified in the sequence using BLAST-CDS. The 3D structure of the protein obtained was predicted using the GalaxyWEB tool, and the ligand binding sites were predicted using the 3DLigandSite tool. Similar conserved domain architectures were determined using NCBI-BLAST Conserved Domain Architecture Retrieval Tool. Immune Epitope Database (IEDB) and Support Vector Machine Tri-peptide (SVMTrip) software tools were used to predict antigenic epitopes from the protein sequence of Domain I of PfAMA1 obtained in the study. The VaxiJen V2.0 bioinformatic tool was used to check for immunogenic properties of the protein sequence of Domain I of PfAMA1 obtained in the study.

### 3. Results

**3.1. Gene Sequence Similarities of Domain I of Plasmodium falciparum AMA1.** In order to investigate gene sequence similarities of Domain I of *Plasmodium falciparum* AMA1 obtained in the study, the bioinformatic tool NCBI-BLAST was used. The 459 bp sequence produced showed high significant similarities to *Plasmodium falciparum* AMA1 gene sequences found in the NCBI database. It showed 96.38% identity with 96% query cover with the *Plasmodium falciparum* 3D7 reference genome (Accession number: NC037282.1) and 99.57% identity after 96% query cover

TABLE 2: Similar conserved amino acid sequences in Domain I of AMA1 in *Plasmodium* species that infect human.

| Amino acid positions | Pf        | Pv        | Pm        | Po        | Pk        |
|----------------------|-----------|-----------|-----------|-----------|-----------|
| 7–13                 | FLKPVAT   | FLKPVAT   | FLTPVAT   | FLKPVAT   | FLTPVAT   |
| 18–26                | LKDGGFAFP | LKDGGFAFP | LKSGGFAFP | LKSGGFAFP | LKEGGFAFP |
| 33–36                | SPMT      | SPMT      | SPVT      | SPIS      | SPIT      |
| 44–47                | YKDN      | YKDN      | YEEH      | YNEN      | YKEN      |
| 53–59                | LDELTLT   | LNDIALC   | LNDLSLC   | LNDMSLC   | LNDIALC   |
| 79–83                | PAVYD     | PAVYD     | PAVYD     | PAVYD     | PAVYD     |
| 101–105              | GPRYC     | GPRYC     | GPRYC     | GPRYC     | GPRYC     |
| 131–136              | YLSKNV    | YLSKNV    | YLSKNV    | YLSKNL    | YLSKNV    |
| 144–149              | CPRKNL    | CPRKNL    | CPRKSL    | CPRNNL    | CPRKNL    |

Pf = *Plasmodium falciparum*; Pv = *Plasmodium vivax*; Pm = *Plasmodium malariae*; Po = *Plasmodium ovale*; Pk = *Plasmodium knowlesi*.




FIGURE 2: 3D protein structural prediction of the 149-amino acid PfAMA1 protein sequence obtained in the study (using galaxy.seoklab.org).

with the *Plasmodium falciparum* apical membrane antigen 1 (AMA1) gene partial CDS of 100 selected sequences in the NCBI database. The 459 bp sequence was deposited into the GenBank database and was assigned a genome (Accession number: OL634842).

**3.2. Identification of Conserved Short Peptides in Domain I of *Plasmodium falciparum* AMA1.** In order to determine the conserved short peptides in Domain I of *Plasmodium falciparum* AMA1 that could be potential drug targets and the hydrophobic pocket of AMA1, the 459 bp gene sequence was translated into its corresponding protein sequence (Figure.S1) using a bioinformatic tool. The protein sequence was used in protein-to-protein BLAST, using the bioinformatic tool NCBI-BLAST to obtain similar protein sequences of Domain I of *Plasmodium* AMA1 in all the human *Plasmodium* species (Figure.S2). The short peptide sequences are conserved across *Plasmodium* species surrounded by a highly polymorphic region [9]. To investigate this, the protein sequence obtained (Figure.S1) was used to compare with all the different protein sequences (Figure.S2) using the bioinformatic tool EMBOSS Needle. The short peptide sequences PAVYD and GPRYC are conserved across the entire *Plasmodium* species infecting human (Table 2). To test




FIGURE 3: Predicted ligand binding sites [11].

whether these conserved short peptide sequences might be the hydrophobic pocket of *Plasmodium* AMA1, the 3D structure of the protein sequence obtained in the study was predicted using a bioinformatic tool (Figure 2). To identify the short peptide sequences that make up the hydrophobic pocket and ligand binding site in the 3D structure of the protein, the bioinformatic tool developed by Wass et al. [11] was used. The short peptide GPRYC was predicted as part of the hydrophobic pocket and ligand binding site (Figure 3). In addition, to predict which of the amino acid residues in the short peptide sequence (GPRYC) might be involved in ligand binding, the bioinformatic tool developed by Wass et al. [11] was used. Cysteine (C) and proline (P) were predicted as more likely to bind to the ligand and interact with it (Table 3).

**3.3. Immunogenic Properties of Domain I of *Plasmodium falciparum* AMA1.** To determine the immunogenic properties of the protein sequence of Domain I of *Plasmodium falciparum* AMA1 obtained in the study, the bioinformatic tools IEDB and SVMTrip were used to predict linear B-cell

TABLE 3: Predicted binding residues that interact with the ligand [11].

| Residue | Amino acid | Conservation (0 and 1) | Solvent accessibility | Probability (0 and 1) |
|---------|------------|------------------------|-----------------------|-----------------------|
| 101     | GLY        | 0.0                    | 35.32                 | 0.99                  |
| 102     | PRO        | 0.0                    | 112.09                | 1.0                   |
| 103     | ARG        | 0.0                    | 202.44                | 0.99                  |
| 104     | TYR        | 0.0                    | 102.35                | 0.81                  |
| 105     | CYS        | 0.0                    | 5.28                  | 1.0                   |
| 106     | ASN        | 0.0                    | 58.82                 | 1.0                   |

epitopes in the protein sequence. The IEDB tool predicted six B-cell epitopes in the sequence (Table 4). The SVMTrip tool predicted six B-cell epitopes but recommended two as indicated by the flags (Table 5).

Common West African HLA antigens associated with protection against severe malaria: HLA-B53, HLA-DQB1\*05:01, and HLA-DRB1\*13:02 [12], were used for T-cell epitope prediction. The sequence shows that it is a good binder for HLA-B53 (the MHC class I binding predictions were made on 11/7/2021 using the IEDB analysis resource NetMHCpan [13]). For MHC class II, the sequence indicates that it is a good binder for HLA-DQB1\*05:01 and HLA-DRB1\*13:02 (the MHC class II predictions were made on 11/7/2021 using the IEDB analysis resource consensus tool [14]). The results from IEDB analyses also indicate that the protein sequence is more likely to be processed naturally by MHC molecules.

To investigate whether the protein sequence obtained in the study is an antigen and an immunogen (protective antigen), the bioinformatic tool VaxiJen V2.0 was used to predict the protective antigen and subunit vaccine sequence. For the parasite antigen, the protective antigen is predicted if the value obtained is greater than 0.5. The result obtained shows that the sequence is more likely to be a protective antigen as the predicted value is 0.5436 (Figure.S3). In addition, to determine whether the protein sequence obtained in the study is conserved across *Plasmodium falciparum*, protein-to-protein BLAST using the bioinformatic tool NCBI-BLAST was performed. The result obtained indicates that the protein sequence is conserved across *Plasmodium falciparum*.

**3.4. Predicted Binding Ligands.** To identify possible future drugs against malaria, the bioinformatic tool developed by Wass et al. [11] was used to identify ligands that can bind to the short peptide sequence GPRYC and to other areas of the 3D structure of the protein obtained in the study. The sulphate ion (Figure 4) was identified as a potential ligand that can bind to the short peptide sequence GPRYCN. Imidazole (Figure 5) was identified as a potential ligand that can bind to the short peptide sequence NL found in the protein 3D structure.

**3.5. Taxonomy.** To determine how the human *Plasmodium* species are related based on Domain I of *Plasmodium* AMA1, the protein sequence obtained in the study (Figure.S1) and those obtained in the NCBI database (Figure.S2) were used in a pairwise comparison using the bioinformatic

tool EMBOSS Needle. The result indicates that *Plasmodium vivax* and *Plasmodium knowlesi* are closely related (83%) identity in their amino acid sequences found in their Domain I of *Plasmodium* AMA1 (Table 6). Pairwise comparison between the major human *Plasmodium* species and some major *Plasmodium* species indicates that *Plasmodium falciparum* and *Plasmodium reichenowi* are closely related (91.3%) identity in their amino acid sequences found in their Domain I of AMA1. *Plasmodium vivax* and *Plasmodium cynomolgi* are closely related (89.3%) identity in their amino acid sequences found in their Domain I of AMA1 (Table.S1).

**3.6. Similar Conserved Domain Architectures.** To predict the function of Domain I of *Plasmodium falciparum* AMA1 obtained in the study, similar conserved domain architectures were obtained from the NCBI database using the protein sequence obtained in the study. These similar conserved domains are apical membrane antigen 1 partial, somatic embryogenesis receptor kinases, and leucocyte tyrosine kinase receptor. Domains are evolutionary conserved units of proteins, are widely used to classify protein sequences, and infer protein functions [15]. So based on these, we hypothesize that Domain I of *Plasmodium falciparum* AMA1 might be an extracellular receptor tyrosine kinase where the receptor pocket might be composed of the short peptide sequences PAVYD and GPRYC.



## 4. Discussion

**4.1. Proposed Molecular Mechanisms for Plasmodium Invasion of Host Cells.** *Plasmodium* uses apical secretory organelles to invade host cells. The invasion of host cells begins with the proteins secreted from the micronemes of the parasite and targeted to the parasite surface where they engage with host cell receptors [16]. This process triggers subsequent secretion of Rhoptry neck proteins from the secretory organelle of the parasite called the rhoptries. These Rhoptry neck proteins consist of RON2, RON4, RON5, and RON8 which are exported to the host cell surface membrane. RON2 is integrated into the host cell surface membrane with its N-terminal domain directed into the cytosol where it is likely retaining RONs 4, 5, and 8 to the cytosol face of the host membrane [17]. RON2 serves as a ligand for micro-nemal-secretory apical membrane antigen 1 (AMA1) secreted from the microneme and exported to the parasite cell membrane shortly before invasion. AMA1 interacts directly with the extracellular C-terminal portion of RON2 [18], resulting in the formation of the moving junction (MJ). The formation of MJ is considered the irreversible attachment

TABLE 4: Linear B-cell epitope prediction using the IEDB tool.

| No. | Start | End | Peptide                      | Length |
|-----|-------|-----|------------------------------|--------|
| 1   | 6     | 34  | TFLKPVATENQDLKDGGFAPPTNPLMSP | 29     |
| 2   | 43    | 54  | LYKDNEYVKNLD                 | 12     |
| 3   | 65    | 85  | NMNPNDKNSNYKYPVYDYE          | 21     |
| 4   | 99    | 112 | NNGPRYCNKDQSKR               | 14     |
| 5   | 121   | 127 | AKDKSFQ                      | 7      |
| 6   | 137   | 146 | VDNWEKVCPR                   | 10     |

TABLE 5: Linear B-cell epitope prediction using the SVMTrip tool.

| Rank | Location | Epitope            | Score | Recommended*  |
|------|----------|--------------------|-------|---|
| 1    | 31–48    | LMSPMTLDHMRHLYKDNE | 1.000 |  |
| 2    | 49–66    | YVKNLDELTLCSRHAGNM | 0.941 |  |
| 3    | 5–22     | TTFLKPVATENQDLKDG  | 0.515 |   |
| 4    | 102–119  | PRYCNKDQSKRNSMFCFR | 0.471 |   |
| 5    | 130–147  | TYLSKNVVDNWEKVCPR  | 0.462 |   |
| 6    | 79–96    | PAVYDYEDKKCHILYIAA | 0.338 |   |

\*The epitopes recommended are labeled by the flags.




FIGURE 4: Sulphate ion (Drug identity: DB14546) bound to the peptide sequence GPRYCN.




FIGURE 5: Imidazole (Drug identity: DB03366) bound to the short peptide NL.

step necessary for successful invasion [19]. The parasite then actively passes through the MJ apparently using an actin-myosin motor [20]. This results in the internalization of the parasite into a parasitophorous vacuole created by the host cell. During MJ formation, RON2 adopts a conformation

TABLE 6: Pairwise comparison of protein sequences of Domain I of AMA1 across human *Plasmodium* species using the pairwise sequence alignment EMBOSS Needle tool.

| Human <i>Plasmodium</i> species pairs | % identity | Scores |
|---------------------------------------|------------|--------|
| Pf/PV                                 | 54         | 466    |
| Pf/Pm                                 | 50         | 445    |
| Pf/Po                                 | 43         | 389    |
| Pf/Pk                                 | 50         | 430    |
| Pv/Pm                                 | 70         | 607    |
| Pv/Po                                 | 70         | 607    |
| Pv/Pk                                 | 83         | 693    |
| Pm/Po                                 | 70         | 598    |
| Pm/Pk                                 | 69         | 578    |
| Po/Pk                                 | 72         | 612    |

Pf = *Plasmodium falciparum*; Pv = *Plasmodium vivax*; Pm = *Plasmodium malariae*; Po = *Plasmodium ovale*; Pk = *Plasmodium knowlesi*.

that enables it to span the host cell membrane such that a disulphide-constrained loop near its C-terminus can interact with AMA1 [21]. Interfering with this RON2-AMA1 interactions blocks parasite invasion of the host cell [22]. However, the molecular processes that lead to the creation of the moving junction and the parasitophorous vacuole are still unclear, as are the peptide sequences of AMA1 that generate the hydrophobic pocket for the RON2 ligand.

The results of this study indicate that the *Plasmodium* AMA1 hydrophobic pocket might be composed of the short peptide sequences GPRYC and PAVYD. One side of the hydrophobic pocket might consist of the short peptide sequence GPRYC. The other side of the hydrophobic pocket might consist of the short peptide sequence PAVYD. G is opposite P, P is opposite A, R is opposite V, Y is opposite Y, and C is opposite D. The short peptide sequence (GPRYC) on one side of the pocket begins with glycine (G) from the inside of the pocket to cysteine (C) on the outside of the pocket. In contrast, on the other side of the pocket, the short peptide sequence (PAVYD) begins from proline (P) from the inside of the pocket to aspartic acid (D) on the outside of

the pocket. Glycine (G) at the hydrophobic pocket permits any combination of side chains which otherwise would have to be excluded because of steric hindrance. For this reason, glycine provides a means for the juxtaposition of the two tyrosine residues in the pocket. Proline (P) plays a role in the formation of the hydrophobic pocket by changing the direction of the polypeptide chains. Proline may also facilitate sequence-specific recognition of RON2 protein by AMA1 without requiring a particular high affinity interaction and facilitate binding of RON2 to AMA1. Prior to RON2 binding, the two tyrosine residues in the pocket might play a role in molecular recognition. This molecular recognition enables AMA1 to identify RON2 in the midst of other host cell membrane surface proteins. Arginine (R) in position 103 and cysteine (C) in position 105 might be involved in the binding of AMA1 to RON2. The previous work [23] has shown that RON2 has a conserved aspartic acid (D) and cysteine (C) that are critical for AMA1 binding to RON2. Based on this, we suggest that the conserved cysteine on AMA1 forms an interchain disulphide bridge with the conserved cysteine in RON2. Since arginine is a positive amino acid and aspartic acid is a negative amino acid, the conserved arginine on AMA1 forms an ionic bond with the conserved aspartic acid on RON2. So, RON2 might be attached to AMA1 with the help of an interchain disulphide bridge and an ionic bond. Since the N-terminal of RON2 is integrated in the host cell membrane, these bonding connections provide a firm attachment of the parasite to the host cell during the gliding movement that ends with the parasitophorous vacuole formation.

The results of this study also suggest that Domain I of *Plasmodium* might be a receptor kinase. The aspartic acid residue (D) on PAVYD might be involved in the regulation of enzymatic activity and the expression of receptor tyrosine kinase after the binding of RON2 to the AMA1 hydrophobic pocket. Valine on PAVYD might promote the activation of tyrosine kinases in the pocket, and this view is supported by the work of Dimaio and Irusta [24]. So based on these, we suggest that the AMA1 hydrophobic pocket might be an extracellular tyrosine kinase-like receptor where binding of RON2 to the pocket activates the kinase activity in the pocket. This activation gives rise to cross phosphorylation of the juxtaposed tyrosine residues (Y) on GPRYC and PAVYD by kinases. This phosphorylation might generate molecular signals that are transmitted to the actin-myosin motor in the cytoplasm of the parasite with the help of the cytoplasmic tail of AMA1. This motor after receiving the signals starts the gliding movement that enables the parasite to move into the pore formed on the host cell membrane resulting in the parasitophorous vacuole. All these claims are totally hypothetical and needed to be confirmed by assays.

The molecular mechanisms by which *Plasmodium* species interact with human host cells during cell invasion have been difficult to explain previously. The lack of this knowledge previously makes the development of a universal malaria vaccine based on AMA1 antigen difficult and also reduces the prospect for the discovery of new antimalarial drugs that target AMA1. This study suggested for the first time the molecular mechanisms by which *Plasmodium*

species invade human host cells and also identified the short peptides GPRYC and PAVYD to be crucial for *Plasmodium* invasion of human host cells. We suggest that smaller ligands or antibodies that bind to GPRYC might block *Plasmodium* invasion of human host cells. Future studies will be necessary to validate this apparent suggestion which will open a new research for the discovery of new drugs and vaccines against malaria.

**4.2. Vaccine Development and Drug Discovery.** The protein sequence (Figure.S1) obtained in the study shows no significant similarity to any human protein in the NCBI database. This makes the sequence a good vaccine antigen because when antibodies are produced against the antigen in the human body, they cannot attack the body's own antigens because of the great diversity. The sequence may contain B-cell epitopes based on the linear B-cell epitopes predicted from the sequence (Tables 3 and 4). The sequence may be processed by body cells and then presented to CD4 and CD8 cells utilizing MHC class II and MHC class I molecules, respectively, according to T-cell epitope predictions. The sequence is an antigen, as evidenced by this. The sequence was further tested for immunogenic properties. The result indicates that the sequence may be an immunogen (Figure. S3). Protective antigens (immunogens) are specifically targeted by the acquired immune response of the host and are able to induce protection in the host against infectious and noninfectious diseases [25]. Protective antigens play important roles as biological markers for disease diagnosis, vaccine development, and analysis of fundamental host immunity against diseases [25]. Most *Plasmodium falciparum* antigens that have been used for vaccine studies are highly immunogenic showing good promise as vaccine candidates, but most of these antigens are also highly polymorphic and elicit parasite strain-specific immune responses. Over the years, it has been difficult to produce an effective vaccine against malaria using AMA1 because of polymorphisms observed in the AMA1 gene [7]. This study provides a protein sequence of Domain I of *Plasmodium falciparum* AMA1 that has immunogenic properties and is conserved across *Plasmodium falciparum*. This protein sequence may serve as a potential vaccine sequence in the future. The protein sequence (Supplementary Figure 1) shows significant similarities to the AMA1 sequences that were used in AdCh63 AMA1, DNA-Ad, and PfAMA1 vaccines that are currently being tested in clinical trials. This protein sequence obtained from this study provides a useful alternative sequence if the clinical trials of the above-mentioned vaccines face difficulties with respect to efficacy.

One of the main obstacles to the global control and eradication of malaria is the establishment and potential spread of artemisinin resistance by human *Plasmodium* species, underscoring the urgent need for the creation of new antimalarial medications. This investigation identified imidazole (Figure 5) and sulphate ion (Figure 4) as two potential future medications for the treatment of malaria. Imidazoles are antifungal drugs that inhibit the synthesis of ergosterol in fungi [26]. Imidazoles have been reported in

previous works of having in vitro activities against *Plasmodium falciparum* [27, 28]. There have been different reports on the mode of actions of imidazoles on *Plasmodium falciparum*, suggesting that imidazoles may act on a variety of targets on *Plasmodium falciparum*. This study for the first time identified a possible target of imidazole on Domain I of *Plasmodium falciparum* AMA1 and also supported the view that imidazoles such as clotrimazole and ketoconazole may in the future be considered possible drugs against malaria.

The sulphate ion (Figure 4) drug is still under development, and the protein target for the drug is not yet known. This drug has been used in clinical trials against respiratory diseases (ClinicalTrials.gov Identifier: NCT02084043). This study identified Domain I of *Plasmodium falciparum* AMA1 as a possible protein target for this drug. This study indicates that this medication should be investigated as a potential malaria treatment in the future. However, in order for this to happen, additional in vitro research will be required to support this apparent recommendation.

**4.3. Taxonomy.** Protein sequence analysis of Domain I of human *Plasmodium* AMA1 reveals a close relationship between *Plasmodium vivax* and *Plasmodium knowlesi*. This might explain why these particular human *Plasmodium* species are the only ones that can bind to the erythrocytes' Duffy antigen receptor for chemokines. *Plasmodium malariae* and *Plasmodium ovale* are closely related to *Plasmodium vivax* than *Plasmodium falciparum* (Table 6). Comparing the protein sequence of Domain I of AMA1 in the major human *Plasmodium* species (*Plasmodium vivax* and *Plasmodium falciparum*) with the protein sequence of Domain I of AMA1 in other major *Plasmodium* species (*Plasmodium berghei*, *Plasmodium cynomolgi*, and *Plasmodium reichenowi*) indicates that *Plasmodium vivax* is closely related to *Plasmodium cynomolgi* (89.3% identity). *Plasmodium vivax*, *Plasmodium knowlesi*, and *Plasmodium cynomolgi* might have originated from a common ancestor. These findings are similar to those obtained by Tachibana et al. [29]. *Plasmodium falciparum* is closely related to *Plasmodium reichenowi* (91.3% identity) than to any of the human *Plasmodium* species suggesting a common ancestor for these two *Plasmodium* species. The result from this study indicates that amino acid sequences of Domain I of human *Plasmodium* AMA1 differ across human *Plasmodium* species.

Even though differences exist among amino acid sequences of Domain I of human *Plasmodium* AMA1, the short peptide sequences PAVYD and GPRYC remain conserved across amino acid sequences of Domain I of human *Plasmodium* AMA1 (Table 2). A study has shown that they appear to be a significant conservation of the invasion apparatus on the level of both ultrastructure and protein associated with apical organelles [30]. These common elements are of particular interest biologically as they constitute the phylogenetic conserved basic machinery for host cell invasion essential for the survival of these obligate intracellular parasites [30]. Single-nucleotide polymorphisms (SNPs) occur in the AMA1 gene across apicomplexan species because AMA1 is a target for host immunity. These polymorphisms might occur as a result of pressure

exerted on AMA1 by the host immune system [31]. These polymorphisms might be immune evasion polymorphisms. Despite these polymorphisms, the invasion ligand that fills the hydrophobic pocket of AMA1 is functionally conserved throughout apicomplexan species. This invasion ligand binds to a conserved sequence of amino acid in RON2 [32]. A study has demonstrated that genetic engineered *Plasmodium falciparum* having *Plasmodium vivax* AMA1 was able to bind to *Plasmodium falciparum* RON2 and invade host cells generating new chimeric *Plasmodium falciparum* [6]. This functional conservation of invasion ligand happens to occur across species of apicomplexans but not among genera as *Plasmodium falciparum* RON2 failed to bind to *Toxoplasma* AMA1 [22]. Thus, the AMA1-RON2 binding is evolutionarily conserved across apicomplexan species. An in vitro study has demonstrated that induced mutation in one of the amino acids in the hydrophobic pocket prevents the binding of AMA1 to a complex of RON2 proteins [33]. The short peptide sequences PAVYD and GPRYC may constitute the conserved basic machinery for human host cell invasion by human *Plasmodium* species.

Each apicomplexan species utilized its own parasite-derived RON2 protein as a receptor rather than a conserved host molecule. Sequence polymorphisms occur in RON2 protein across apicomplexan genera [22] and across apicomplexan species [34]. These single-nucleotide polymorphisms might be immune evasion polymorphisms as RON2 is a target for host immunity [34]. Although RON2 protein has variations in different apicomplexan species, the peptide sequence of RON2 protein that binds to the AMA1 hydrophobic pocket is conserved across species of apicomplexans [32, 35].

## 5. Conclusion

In this investigation, the short peptides GPRYC and PAVYD that are conserved throughout *Plasmodium* AMA1 Domain I were discovered. It is possible that GPRYC and PAVYD make up *Plasmodium* AMA1's hydrophobic pocket. Additionally, the findings imply that the hydrophobic pocket of *Plasmodium* AMA1 may represent an external receptor tyrosine kinase. This research also sheds important light on a prospective malaria vaccine antigen sequence, potential future malaria drugs, and molecular mechanisms of *Plasmodium* penetration of host cells. Our research sheds light on malaria treatment and vaccine development in a way that has not been previously discussed.

## Data Availability

All data generated or analysed during this study are included in this manuscript.

## Ethical Approval

The study received ethical approval from the Institutional Review Board of the Faculty of Health Science University of Buea (Reference number: 2019/872-11/UB/SG/IRB/FHS). Administrative authorization was obtained from the North West Regional Delegation of Public Health Cameroon



(Reference number: 79/L/NWR/RDPH). Only children who fulfilled the specific inclusion criteria and had assent given by their parents or guardians after adequate sensitization on the research objectives and possible risks and benefits were enrolled into the study.

## Conflicts of Interest

The authors declare that they have no conflicts of interest.

## Authors' Contributions

CRA and DNA conceived and designed the experiments. CRA carried out the experiments and produced the first draft of the manuscripts. CRA and RAS performed molecular analysis of the data. CRA and CJT participated in sample collection and genotyping. All authors read and approved the final copy of the manuscript.

## Acknowledgments

The authors appreciate the blood donations from the malaria patients and also appreciate the staff at the University of Buea's Laboratory of Molecular Parasitology for their assistance with the genotyping of the AMA1 gene. Dr. Fon Tata's material assistance is also acknowledged.

## Supplementary Materials

The protein sequence obtained in the study is that of Domain I of *Plasmodium falciparum* AMA1 (Figure. S1). This protein sequence is an immunogen and is one of the targets for drugs like imidazole and the sulphate ion. Using the bioinformatic program VaxiJen V2.0, the protein sequence obtained from the study was examined for immunological characteristics because not all antigens are immunogens. The outcome shows that the protein sequence is an immunogen also known as the protective antigen (Figure.S3). The sequence is therefore a promising option for a malaria vaccine. The sequence is conserved across *Plasmodium falciparum*. Different amino acid sequences of *Plasmodium* AMA1 Domain I exist. GPRYC and PAVYD, two short peptide sequences, are conserved in all *Plasmodium* species (Figure.S2). These short peptide sequences may make up *Plasmodium* AMA1's hydrophobic pocket. Evaluating the Domain I protein sequences of the other important *Plasmodium* species and the major human *Plasmodium* species, the findings show that *Plasmodium falciparum* and *Plasmodium reichenowi* are closely related and that *Plasmodium vivax* and *Plasmodium cynomolgi* are closely related (Table.S1). (Supplementary Materials)

## References

- [1] R. W. Snow, "Global malaria eradication and importance of *Plasmodium falciparum* epidemiology in Africa," *BMC Medicine*, vol. 13, no. 1, p. 23, 2015.
- [2] WHO, "World Malaria Report," 2021, <https://www.who.int/publications/i/item/9789240040496>.
- [3] RTSS Clinical Trials Partnership, "Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial," *Lancet*, vol. 386, no. 9988, pp. 31–45, 2015.
- [4] A. N. Hodder, P. E. Crewther, M. L. S. M. Matthew et al., "The disulfide bond structure of *Plasmodium* apical membrane antigen-1," *Journal of Biological Chemistry*, vol. 271, no. 46, pp. 29446–29452, 1996.
- [5] A. E. Abdolaziz Gharaei, A. Gharaei, and K. Saryazdi, "Allelic Diversity of polymorphic AMA-1 (Apical membrane Antigen1) vaccine candidate antigen of *Plasmodium falciparum* in two population of imported and indigenous cases in South-East of Iran using Nested PCR and RFLP," *Journal of Tropical Diseases*, vol. 02, no. 5, p. 5, 2014.
- [6] D. R. Drew, P. R. Seuders, G. Weiss, P. R. Gilson, B. S. Crabb, and J. G. Beeson, "Functional conservation of the AMA1 host-cell invasion ligand between *Plasmodium falciparum* and *Plasmodium vivax*: a novel plate form to accelerate vaccine and drug development," *The Journal of Infectious Diseases*, vol. 217, pp. 1–10, 2017.
- [7] A. A. Escalante, H. M. Grebert, S. C. Chaiyaroj et al., "Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of *Plasmodium falciparum*. X. Asembo Bay Cohort Project," *Molecular and Biochemical Parasitology*, vol. 113, no. 2, pp. 279–287, 2001.
- [8] C. H. Kocken, D. L. Narum, A. Massougbdjji et al., "Molecular characterization of *Plasmodium reichenowi* apical membrane antigen-1 (AMA1) comparison with *Plasmodium falciparum* AMA-1 and antibody mediated inhibition of red cell invasion," *Molecular and Biochemical Parasitology*, vol. 109, no. 2, pp. 147–156, 2000.
- [9] N. C. Bittencourt, A. B. I. E. d Silva, N. S. Virgili et al., "*Plasmodium vivax* AMA1: Implications of distinct haplotypes for immune response," *PLoS Neglected Tropical Diseases*, vol. 14, no. 7, Article ID e0008471, 2020.
- [10] C. R. Achungu, T. N. Akenji, T. Apinjoh, and S. Wanji, "Re-emergence of Chloroquine sensitive *Plasmodium falciparum* after several years of chloroquine withdrawal in Bamenda, North West Cameroon," *EC Microbiology*, vol. 14, no. 12, pp. 831–836, 2018.
- [11] M. N. Wass, L. A. Kelley, and M. J. E. Sternberg, "3D ligand site: predicting ligand binding sites using similar structures," *Nucleic Acids Research*, vol. 38, no. suppl\_2, pp. W469–W473, 2010.
- [12] A. V. S. Hill, C. E. M. Allsopp, D. Kwiatkowski et al., "Common West African HLA antigens are associated with protection from severe malaria," *Nature*, vol. 352, no. 6336, pp. 595–600, 1991.
- [13] P. Wang, J. Sidney, Y. Kim et al., "Peptide binding predictions for HLA DR, DP and DQ molecules," *BMC Bioinformatics*, vol. 11, no. 1, p. 568, 2010.
- [14] B. Reynisson, B. Alvarez, S. Paul, B. Peters, and M. Nielsen, "NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data," *Nucleic Acids Research*, vol. 48, no. W1, pp. 449–454, 2020.
- [15] J. H. Fong and A. Marchler-Bauer, "Protein subfamily assignment using the conserved domain Database," *BMC Research Notes*, vol. 1, p. 114, 2008.
- [16] D. Gaur and C. E. Chitnis, "Molecular interactions and signaling mechanisms during erythrocyte invasion by malaria

- parasites," *Current Opinion in Microbiology*, vol. 14, no. 4, pp. 422–428, 2011.
- [17] S. Besteiro, A. Michelin, J. Poncet, J. F. Dubremetz, and M. Lebrun, "Export of a *Toxoplasma gondii* rhoptry neck protein complex at the host cell membrane to form the moving Junction during invasion," *PLoS Pathogens*, vol. 5, no. 2, Article ID e1000309, 2009.
- [18] S. Besteiro, J. F. Dubremetz, and M. Lebrun, "The moving Junction of apicomplexan parasites: a key structure for invasion," *Cellular Microbiology*, vol. 13, no. 6, pp. 797–805, 2011.
- [19] M. H. Lamarque, M. Roques, M. Kong-Hap et al., "Plasticity and redundancy among AMA–RON pairs ensure host cell entry of *Toxoplasma* parasites," *Nature Communications*, vol. 5, no. 1, p. 4098, 2014.
- [20] L. D. Sibley, "How apicomplexan parasites move in and out of cells," *Current Opinion in Biotechnology*, vol. 21, no. 5, pp. 592–598, 2010.
- [21] C. R. Collins and M. J. Blackman, "Apicomplexan AMA1 in host cell invasion: a model at the Junction?" *Cell Host & Microbe*, vol. 10, no. 6, pp. 531–533, 2011.
- [22] M. Lamarque, S. Besteiro, J. Papoin et al., "The RON2-AMA1 interaction is a critical step in moving Junction-dependent invasion by Apicomplexan parasites," *PLoS Pathogens*, vol. 7, no. 2, Article ID e1001276, 2011.
- [23] M. L. Tonkin, M. Roques, M. H. Lamarque et al., "Host cell invasion by Apicomplexan parasites: Insights from the co-structure of AMA1 with a RON2 peptide," *Science*, vol. 333, no. 6041, pp. 463–467, 2011.
- [24] D. Dimaio and P. M. Irusta, "A single amino acid substitution in WW-like domain of diverse member of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation," *EMBO Journal*, vol. 17, no. 23, pp. 6912–6923, 1998.
- [25] B. Yang, S. Sayers, Z. Xiang, and Y. He, "Protegen: a web-based protective antigen data base and analysis system," *Nucleic Acids Research*, vol. 39, no. suppl\_1, pp. D1073–D1078, 2011.
- [26] H. Van den Bossche, G. Willemsens, W. Cools, F. Cornelissen, W. F. Lauwers, and J. M. van Cutsem, "In vitro and in vivo effects of the antimycotic drug Ketoconazole on sterol synthesis," *Antimicrobial Agents and Chemotherapy*, vol. 17, no. 6, pp. 922–928, 1980.
- [27] T. Tiffert, H. Ginsburg, M. Krugliak, B. C. Elford, and V. L. Lew, "Potent antimalarial activity of Clotrimazole in in vitro cultures of *Plasmodium falciparum*," *Proceedings of the National Academy of Sciences*, vol. 97, no. 1, pp. 331–336, 2000.
- [28] M. A. Pfaller and D. J. Krogstad, "Imidazole and Polyene activity against chloroquine-resistance *Plasmodium falciparum*," *Journal of Infectious Diseases*, vol. 144, no. 4, pp. 372–375, 1981.
- [29] S. I. Tachibana, S. A. Sullivan, S. Kawai et al., "*Plasmodium cynomolgi* genome sequences provide insight in to *Plasmodium vivax* and the monkey malaria clade," *Nature Genetics*, vol. 44, no. 9, pp. 1051–1055, 2012.
- [30] A. B. Hehl, C. Lekutis, M. E. Grigg et al., "*Toxoplasma gondii*: Homologue of *Plasmodium* Apical membrane Antigen1 is involved in invasion of host cells," *Infection and Immunity*, vol. 68, no. 12, pp. 7078–7086, 2000.
- [31] M. J. Mackinnon and K. Marsh, "The selection Landscape of malaria parasites," *Science*, vol. 328, no. 5980, pp. 866–871, 2010.
- [32] P. Srinivasan, W. L. Beatty, A. Diouf et al., "Binding of *Plasmodium* merozoite proteins RON2 and AMA1 triggers commitment to invasion," *Proceedings of the National Academy of Sciences*, vol. 108, no. 32, pp. 13275–13280, 2011.
- [33] C. R. Collins, C. Withers-Martinez, F. Hackett, and M. J. Blackman, "An inhibitory antibody blocks interactions between components of the malaria invasion machinery," *PLoS pathogens*, vol. 5, no. 1, Article ID e1000273, 2009.
- [34] N. C. Bittencourt, J. A. Leite, A. B. I. E. Silva et al., "Genetic sequence characterization and naturally acquired immune response to *Plasmodium vivax* rhotry neck proptein 2 (RON2)," *Malaria Journal*, vol. 17, no. 1, p. 401, 2018.
- [35] M. E. Hossain, S. Dhawan, and A. Mohammed, "The cysteine-rich regions of *Plasmodium falciparum* RON2 bind to host erythrocyte and AMA1 during merozoites invasion," *Parasitology Research*, vol. 110, no. 5, pp. 1711–1721, 2012.
- [36] V. M. Marshall, L. Zhang, R. F. Anders, and R. L. Coppel, "Diversity of the vaccine candidate AMA-1 of *Plasmodium falciparum*<sup>1</sup>," *Molecular and Biochemical Parasitology*, vol. 77, no. 1, pp. 109–113, 1996.